Muscle Relaxants in Infants and Children- How They Differ From Adults? - PowerPoint PPT Presentation

1 / 40
About This Presentation
Title:

Muscle Relaxants in Infants and Children- How They Differ From Adults?

Description:

Muscle Relaxants in Infants and Children- How They Differ From Adults? Mohamed Naguib, MD Department of Anesthesia College of Medicine University of Iowa – PowerPoint PPT presentation

Number of Views:131
Avg rating:3.0/5.0
Slides: 41
Provided by: Moham59
Category:

less

Transcript and Presenter's Notes

Title: Muscle Relaxants in Infants and Children- How They Differ From Adults?


1
Muscle Relaxants in Infants and Children- How
They Differ From Adults?
  • Mohamed Naguib, MD
  • Department of Anesthesia
  • College of Medicine
  • University of Iowa

2
  • Structural and functional development of NMJ
  • Postnatal maturation of NMJ
  • Pharmacokinetic considerations
  • Succinylcholine in pediatric anesthesia
  • Nondepolarizing neuromuscular blocking drugs in
    pediatric anesthesia

3
  1. Starts at 8 weeks of gestation
  2. Myoblasts arise from the somite, motor axons from
    somata in the neural tube, and Schwann cells from
    the neural crest
  3. All three cells travel to meet at the NMJ

4
  1. Myoblasts fuse to form myotubes
  2. Myotubes are approached by motor axons
  3. Followed by Schwann cells

5
Initial contacts are unspecialized, yet
capable of rudimentary transmission
6
  • After encountering the muscle surface the
    motor axon
  • stops its growth
  • begins its characteristic differentiation into a
    presynaptic terminal
  • inducing formation of a motor endplate on the
    muscle surface

7
Formation of the NMJ depends on a series of
reciprocal inductive interactions between the
motor neuron and the muscle cell
8
MuSK muscle-specific kinase MASC
MuSK-accessory specificity component ARIA
AChR-inducing activity
9
(No Transcript)
10
  • Animals lacking either agrin or MuSK ? no NMJs
  • Generally immobile
  • Unable to breathe
  • Die at birth

11
NMJ
1 2 3
50 nm
Subsynaptic nuclei express a unique set of genes
Note stands of basal lamina stretching
between the nerve terminal and postsynaptic
membranes - rich in AChE
12
EM Analysis of nAChR
Synapse
43K
Cytoplasm
13
(No Transcript)
14
Changes in AChR properties during development
Age Turnover Subunits
Pre-innervation lt 14 days I.U. Fast a, b, g, d
NMJ 16 days I.U. Fast a, b, g, d
birth Slow a, b, g, d
2 weeks-adult Slow a, b, d, e
Denervated extrajunctional Fast a b, g, d
15
Structural and Functional Development
  • Type I fibers slow, high oxidative
    Marathon-fibers
  • More sensitive to NDMRs
  • In the diaphragm, it constitutes
  • 14 in premature
  • 26 in full-term neonates
  • 55 in adults
  • The diaphragm is more active than the peripheral
    muscles during NM block in neonates

16
Structural and Functional Development
  • In neonates
  • NM transmission is immature until the age of 2
    months
  • Response to tetanic stimulation and the rate of
    muscle contraction lt older children
  • Greater individual variability to MRs

17
Body Composition During Growth
  • In neonates
  • Total body water, ECF volume, and blood volume
    are relatively larger on a weight basis than they
    are in older patients
  • Muscle mass is smaller
  • MRs are distributed to a volume that mirrors ECF
    compartment

18
Body Composition During Growth
Premature Full Term Adult
TBW ( body wt) 83 73 60
ECF ( body wt) 62 44 20
Blood Vol (ml/kg) 60 85-105 70
ICW ( body wt) 25 33 40
Muscle Mass ( body wt) 15 20 50
Fat ( body wt) 3 12 15
19
  • Some NDMRs and/or their metabolites are
    excreted in the urine, or in the bile

20
  1. Neonatal hepatic enzyme systems are incompletely
    developed or absent
  2. The ability to oxidize or reduce drugs is
    deficient in neonates, but increase to adult
    levels within a few days of life
  3. Conjugative processes are severely limited at
    birth but mature by 3 months of age
  4. The ability to hydrolyze substrates is as
    effective as in adults

21
Succinylcholine
  • In November 1994, FDA mandated the change in the
    Sch package insert. To quote
  • Except when used for emergency tracheal
    intubation or in instances where immediate
    securing of the airway is necessary, Sch is
    contraindicated in children and adolescent
    patients

22
Succinylcholine
  • In March 1995, the relative contraindication has
    been replaced with a boxed warning

Warning Risk of Cardiac Arrest From Hyperkalemic Rhabdomyolysis
23
Sch and Hyperkalemic Cardiac Arrest
  • A healthy appearing infant or child lt 9 yr
  • Undiagnosed myopathy (Duchennes Dystrophy)
  • Peaked T waves, ventricular dysrhythmias
  • Cardiac arrest and death

24
Sch and Hyperkalemic Cardiac Arrest
  • Management
  • Routine resuscitation measures are likely to be
    unsuccessful
  • I.V. calcium, insulin and glucose, bicarbonate,
    with hyperventilation

25
Sch and Incomplete Jaw Relaxation
  • This phenomenon has been described in children
    who were anesthetized with halothane and
    paralyzed with Sch
  • It has also been called masseter muscle
    rigidity (MMR), masseter spasm, or trismus
  • MMR or masseter spasm may be regarded as an
    early sign of MH

26
Sch and Incomplete Jaw Relaxation
  • Most existing studies are retrospective and lack
    agreement on the magnitude and incidence of this
    phenomenon
  • The reports suggested that the incidence of MMR
    in children receiving succinylcholine is 1
  • Other studies report a 50 association between
    MMR and susceptibility to malignant hyperthermia

27
Sch and Incomplete Jaw Relaxation
  • This means that either the susceptibility to MH
    is much greater than is generally believed, or
    the diagnosis of masseter spasm was incorrectly
    made in normal patients

28
Sch and Incomplete Jaw Relaxation
  • It is probable that the high incidence of MMR
    reported by some investigators was the result of
    inadequate doses of succinylcholine administered
    to children
  • In the most recent prospective study, the
    incidence of MMR was reported to be 0.2
  • Anesthesiology 1994 8199-103

29
Succinylcholine
  • When dosage is calculated on a weight basis
    infants gt children gt adults
  • No difference when Sch is given on a surface area
    basis (40 mg/m2)
  • Phase II block may develop (? Dose)

30
(No Transcript)
31
Succinylcholine
  • PCHE conc. in neonates are about the half those
    of the adults
  • Fasciculations are rarely seen in neonates
  • The intensity of the NM block after Sch is
    increasing throughout childhood

32
NDMRs
  • Increased sensitivity in neonates and infants
    and relative resistance in children due to
    changes in drug distribution and muscle mass in
    these age groups

33
NDMRs
  • The fat compartment
  • increases by 2-3 times during the first year of
    life
  • diminishes towards puberty
  • The muscle compartment
  • decreases during the first year of life
  • increases 2-3 times by the end of active growth
    phase

34
NDMRs
  • Adults have more fat and less muscle tissue than
    children
  • When we give a MR on a body weight basis, the
    greatest dose may be needed by children (they
    have the least fat and the most muscle tissue
    compared with other age groups)

35
(No Transcript)
36
(No Transcript)
37
(No Transcript)
38
(No Transcript)
39
Conclusions
  • Developmental changes occur in the human NM
    junction for a least several months after birth
  • Onset of paralysis is more rapid in infants gt
    children gt adults
  • Recovery is dependent on the characteristics of
    NM blocker used

40
Our knowledge can only be finite, while our
ignorance must necessarily be infinite
Proceedings of the British Academy 1960, 4669
Write a Comment
User Comments (0)
About PowerShow.com